Literature DB >> 2285638

Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension.

M Konishi1, M Sakakura, N Tsushima.   

Abstract

Ketanserin, a serotonin antagonist, has recently been developed. This agent produces antihemagglutination and dilation of blood vessels. Blood pressure is also lowered by ketanserin. We investigated the effect of ketanserin on microhemodynamics and hemorheology in essential hypertension. Twenty patients with essential hypertension (8 males; 12 females; average age +/- SE-56.2 +/- 2.5 years). A single dose of 10 mg ketanserin was given orally to each patient, without breakfast, on the experiment day. Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94.5 sec-1) and at low shear rate (0.376 sec-1), with no change in plasma viscosities; significant shortening of plasma passage times; and marked decreases in blood concentrations of total protein, albumin, and globulin. These data suggest that ketanserin beneficially affects microhemodynamics and hemorheology.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285638     DOI: 10.1007/bf00053438

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  4 in total

1.  Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.

Authors:  J R Seibold; C A Terregino
Journal:  J Rheumatol       Date:  1986-04       Impact factor: 4.666

2.  Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats.

Authors:  H O Kalkman; P B Timmermans; P A Van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

3.  Improved filtration method for red cell deformability measurement.

Authors:  Y Kikuchi; T Arai; T Koyama
Journal:  Med Biol Eng Comput       Date:  1983-05       Impact factor: 2.602

4.  Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.

Authors:  R Fagard; R Fiocchi; P Lijnen; J Staessen; E Moerman; A de Schaepdryver; A Amery
Journal:  Br Heart J       Date:  1984-02
  4 in total
  1 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.